Andrew Gross, MD

Professor

As the Rheumatology Clinic Chief at UCSF, I am responsible for all aspects of rheumatology clinical and teaching activities. I am committed to comprehensively aligning the rheumatology clinical program for ongoing success in all three of the traditional domains of academic medicine – clinical care, research and education.

I am committed to:

1. Delivery of World Class Patient Care. UCSF Rheumatology continues to be recognized by "US News & World Report" as one of the 10 best hospitals in rheumatology. I see patients with all forms of rheumatic disease. I have special interest in managing rheumatoid arthritis, systemic lupus erythematosus (SLE), and I also participate in the scleroderma program at UCSF.

2. Delivering outstanding training and education programs in rheumatic disease for rheumatology fellows, internal medicine residents and medical students. I work closely with the Rheumatology Fellowship Program Director, Dr. David Daikh, to coordinate the one of the premier fellowships in rheumatology training. The program includes bedside teaching, post-clinic conferences, and a comprehensive didactic teaching program.

3. Fostering research in rheumatic disease.

We are developing cohorts of patients with rheumatoid arthritis, ankylosing spondylitis, SLE, systemic vasculitis, and scleroderma to facilitate studies of these diseases. I have worked closely with the principle investigators of these studies, study coordinators and clinic staff to facilitate patient recruitment and data collection. These efforts led to the creation of the Rheumatoid Arthritis Center of Excellence, a partnership between UCSF Rheumatology, Stanford University Rheumatology and the Northern California Chapter of the Arthritis Foundation to facilitate research in RA.

I am also committed to facilitating a stronger translational research program in the immunology community at UCSF. In addition to collaborating with members of the immunology program at UCSF to facilitate the development of translational research projects, I am also directly collaborating with researchers at UCSF to investigate mechanism of immune deregulation that contribute to the development of SLE.

Specific Research Interests

I have three broach research interests:

1. I have a long time interest in studying immune deregulation in patients with SLE. I previously invested B cell signaling in mouse models of SLE in the laboratory of Anthony DeFranco, PhD., and I now supporting the efforts of Dr. Franziska Matzkies (UCSF Rheumatology) and Dr. Michelle Hermiston (UCSF Pediatric Hematology) to extend my observations by investigating whether patients with SLE have perturbation in B cell signaling, and whether this is due to genetic variation in the expression and function of signaling proteins in these cells.

I am also collaborating with Dr. Charles Craik in the UCSF Department of Pharmaceutical Chemical Biology investigating neutrophil function in patients with lupus and rheumatoid arthritis.

2. A second area of interest for me is Rheumatoid Arthritis. As director of the Rheumatoid Arthritis Clinic at UCSF, I have the opportunity to collaborate with Dr. John Imboden at SFGH and rheumatologists at Stanford University as members of the Northern California Arthritis Foundation RA Center of Excellence (RA-COE). The RA-COE is engaged in a number of projects including investigation of the mechanisms causing patients with RA to have high risk of atherosclerotic disease. I am also collaborating with members of UCSF Pulmonary Medicine to characterize the progression of interstitial lung disease in patients with RA as well as to investigate the epigenetics of this disease.

3. A third area of interest for me is Scleroderma. I am collaborating with members of UCSF rheumatology, pulmonology, and dermatology in the development of a cohort of scleroderma patients to investigate the genetic mechanisms leading to the development of this disease.
Education
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
M.D., 05/1996 - Medicine, Tufts University School of Medicine
B.S., 05/1991 - Biology, Bates College
Websites
Publications
  1. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease.
  2. A Case of Unilateral Coccidioidal Chorioretinitis in a Patient with HIV-Associated Meningoencephalitis.
  3. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.
  4. New presentation of autoimmune hepatitis with erythema multiforme.
  5. Successful treatment of mucous membrane pemphigoid with bortezomib.
  6. Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy.
  7. Endoscopy is of low yield in the identification of gastrointestinal neoplasia in patients with dermatomyositis: A cross-sectional study.
  8. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.
  9. Management of Uveitis and Scleritis in Necrobiotic Xanthogranuloma.
  10. Validity and Responsiveness of a 10-Item Patient-Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population.
  11. Gingival pustules and sterile diffuse sclerosing osteomyelitis as a feature of synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome.
  12. Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice.
  13. Omental infarction preceded by anatomically upturned omentum.
  14. Voriconazole-induced periostitis in two post-transplant patients.
  15. Lyn deficiency affects B-cell maturation as well as survival.
  16. Progressive craniofacial bone loss after cosmetic surgery at the forehead.
  17. Elevated BCR signaling and decreased survival of Lyn-deficient transitional and follicular B cells.
  18. Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance.
  19. Six refractory lupus patients treated with rituximab: a case series.
  20. EBV and systemic lupus erythematosus: a new perspective.